<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632616</url>
  </required_header>
  <id_info>
    <org_study_id>16-1816</org_study_id>
    <nct_id>NCT03632616</nct_id>
  </id_info>
  <brief_title>Quality of Life Assessment of Chronic Pancreatitis Endoscopic Interventions</brief_title>
  <acronym>QOLAPI</acronym>
  <official_title>Quality of Life Evaluation of Endoscopic Interventions in Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the effect of endoscopic interventions on quality of life in
      patients with chronic pancreatitis. Quality of life will be evaluated using the PANQOLI, a
      validated quality of life instrument specific to chronic pancreatitis. Endoscopic
      interventions will include pancreatic duct dilation and stenting, celiac plexus block,
      lithotripsy and removal of pancreatic duct stones, and pseudocyst drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective cohort study assessing the impact of endoscopic
      interventions on patients with chronic pancreatitis. Patients with chronic pancreatitis
      referred for endoscopic treatment, including pancreatic duct dilation and stenting,
      pseudocyst drainage, celiac plexus blocks, and pseudocyst drainage/necrosectomy will be
      enrolled in this study. They will receive a baseline evaluation using the PANQOLI, a chronic
      pancreatitis-specific quality of life instrument, in addition to a visual analog scale to
      measure their pain. Demographic and endoscopic features will be collected in addition to pain
      medication use. Patients will receive follow-up at 1, 3, and 6 months post-intervention
      consisting of the PANQOLI, visual analog scale for pain, and pain medication use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life using the PANQOLI (PANcreatitis Quality of Life Instrument)</measure>
    <time_frame>The outcome will be measured at 1, 3, and 6 months post-intervention.</time_frame>
    <description>The primary outcome will be the change in quality of life using the PANQOLI (PANcreatitis Quality of Life Instrument) after endoscopic intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain level using the Visual Analog Scale (VAS) for pain.</measure>
    <time_frame>The outcome will be measured at 1, 3, and 6 months post-intervention.</time_frame>
    <description>The secondary outcome will include the change in pain using the Visual Analog Scale (VAS) for pain after endoscopic intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain medication use</measure>
    <time_frame>The outcome will be measured at 1, 3, and 6 months post-intervention.</time_frame>
    <description>The secondary outcome will include the change in pain medication use after endoscopic intervention.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PANQOLI (quality of life instrument)</intervention_name>
    <description>A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, and 6 months post-intervention.</description>
    <other_name>Visual Analog Scale for pain</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with painful chronic pancreatitis who are
        being referred for endoscopic treatment to reduce their pain.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with painful chronic pancreatitis, defined as either 1) the presence of
             pancreatic calcifications on cross-sectional imaging, 2) morphologic changes
             consistent with the Rosemont criteria on endoscopic ultrasound, or 3) endoscopic
             pancreatic function test results consistent with decreased pancreatic function.

        Exclusion Criteria:

          -  Pregnant females

          -  Prisoners

          -  Patients under the age of 18

          -  Patients lacking the capacity to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Samuel Y Han, MD</last_name>
    <phone>617-640-1495</phone>
    <email>samuel.han@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eze Ezekwe, BA</last_name>
    <email>Eze.Ezekwe@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Han, MD</last_name>
      <phone>617-640-1495</phone>
      <email>samuel.han@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Raj J Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Y Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahya Faghih, MD</last_name>
      <email>mfaghih2@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Vikesh Singh, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic pancreatitis</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

